Correlation Between BioInvent International and Sprint Bioscience

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BioInvent International and Sprint Bioscience at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioInvent International and Sprint Bioscience into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BioInvent International AB and Sprint Bioscience AB, you can compare the effects of market volatilities on BioInvent International and Sprint Bioscience and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioInvent International with a short position of Sprint Bioscience. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioInvent International and Sprint Bioscience.

Diversification Opportunities for BioInvent International and Sprint Bioscience

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between BioInvent and Sprint is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding BioInvent International AB and Sprint Bioscience AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sprint Bioscience and BioInvent International is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BioInvent International AB are associated (or correlated) with Sprint Bioscience. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sprint Bioscience has no effect on the direction of BioInvent International i.e., BioInvent International and Sprint Bioscience go up and down completely randomly.

Pair Corralation between BioInvent International and Sprint Bioscience

Assuming the 90 days trading horizon BioInvent International is expected to generate 1.53 times less return on investment than Sprint Bioscience. But when comparing it to its historical volatility, BioInvent International AB is 1.04 times less risky than Sprint Bioscience. It trades about 0.09 of its potential returns per unit of risk. Sprint Bioscience AB is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  44.00  in Sprint Bioscience AB on May 13, 2025 and sell it today you would earn a total of  16.00  from holding Sprint Bioscience AB or generate 36.36% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

BioInvent International AB  vs.  Sprint Bioscience AB

 Performance 
       Timeline  
BioInvent International 

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in BioInvent International AB are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, BioInvent International unveiled solid returns over the last few months and may actually be approaching a breakup point.
Sprint Bioscience 

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point.

BioInvent International and Sprint Bioscience Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BioInvent International and Sprint Bioscience

The main advantage of trading using opposite BioInvent International and Sprint Bioscience positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioInvent International position performs unexpectedly, Sprint Bioscience can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sprint Bioscience will offset losses from the drop in Sprint Bioscience's long position.
The idea behind BioInvent International AB and Sprint Bioscience AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance